Striatal and peripheral dopaminergic alterations related to cognitive impairment in patients with schizophrenia.

ABSTRACT:

Background

Cognitive impairment, a major determinant of poor functioning in schizophrenia, had limited responses to existing antipsychotic drugs. The limited efficacy could be due to regional differences in the dysregulation of the dopamine system. This study investigated striatal and peripheral dopaminergic makers in schizophrenia and their relationship with cognitive impairment.

Methods

Thirty-three patients with schizophrenia and 36 age- and sex-matched healthy controls (HC) participated. We evaluated their cognitive performance, examined the availability of striatal dopamine transporter (DAT) using single-photon emission computed tomography with 99mTc-TRODAT, and measured plasma levels of dopaminergic precursors (phenylalanine and tyrosine) and three branched-chain amino

SUBMITTER: Yang KC 

PROVIDER: S-EPMC11650164 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature